Recent Updates — PLSE
Pulse Biosciences announced a commercial and clinical partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida. The agreement allows the center to treat patients using the company's proprietary nPulse Vybrance Percutaneous Electrode System for symptomatic benign thyroid nodules as part of its controlled market development strategy. Additionally, Pulse Biosciences will collaborate with the center to generate real-world outcomes data and conduct formal clinical studies evaluating nanosecond pulsed field ablation energy for this indication. This partnership expands access to the technology in a high-volume regional hub while supporting evidence generation for broader adoption. Pulse Biosciences is a bioelectric medicine company developing proprietary nanosecond pulsed field ablation technology for medical treatments.
Pulse Biosciences announced that its NANOPULSE-AF Study has reached the target enrollment of 164 evaluable patients across 15 clinical sites. The prospective, multicenter, non-randomized IDE pivotal investigation evaluates the safety and effectiveness of the nPulse Cardiac Catheter System for treating drug-resistant, symptomatic, paroxysmal atrial fibrillation. Enrollment was completed three months ahead of schedule, with primary endpoints to be assessed at 6 and 12 months post-ablation. Pulse Biosciences is a bioelectric medicine company developing nanosecond pulsed field ablation technology for cardiac arrhythmia treatment.
Pulse Biosciences entered into a new equity distribution agreement with Mizuho Securities USA LLC on September 15, 2026, establishing an at-the-market offering program allowing the sale of up to $85 million in common stock. The company terminated its prior at-the-market offering program with TD Cowen, under which approximately $1.0 million remained unsold as of the termination date. This new agreement supplements an existing August 2026 Mizuho program, through which the company has already sold shares totaling approximately $68.8 million. Pulse Biosciences operates in the medical device industry, developing electroporation technologies for cancer treatment.
Pulse Biosciences, Inc. announced the completion of patient enrollment in its PRECISE-BTN clinical study on September 15, 2026, following an expansion from 50 to 100 patients across three U.S. sites: Sarasota Memorial Health Care System, NYU Langone Health, and Weill Cornell Medicine. The first enrolled patient completed their final 12-month follow-up visit in August 2026. The study evaluates the nPulse Vybrance Percutaneous Electrode System for treating symptomatic benign thyroid nodules, with endpoints including safety, volume reduction, and quality of life improvements. Pulse Biosciences is a medical device company developing nanosecond pulsed field ablation technology.
Pulse Biosciences, Inc. entered into an equity distribution agreement with Mizuho Securities USA LLC on August 6, 2026, establishing a sales facility to offer and sell shares of its common stock from time to time. The company may issue up to $75,000,000 in aggregate offering price under this arrangement, though it is not obligated to sell any specific amount. Mizuho will act as sales agent using commercially reasonable efforts to sell shares via at-the-market offerings or other permitted methods, charging a commission of up to 3.0% of the gross sales price. The company may suspend solicitations and offers at any time. This equity issuance capability is facilitated through an effective Form S-3 registration statement filed in February 2026. Pulse Biosciences, Inc. operates in the medical device industry, developing electroporation technologies for cancer treatment.
Pulse Biosciences reported second quarter 2026 financial results and business updates. The company raised $46.8 million in net proceeds through its at-the-market equity program during the quarter, bringing cash and cash equivalents to $101.6 million as of June 30, 2026. Total revenue was $0.4 million against GAAP costs and expenses of $25.7 million, resulting in a GAAP net loss of $24.7 million. Clinically, the NANOPULSE-AF pivotal study surpassed halfway enrollment with over 82 evaluable patients, targeting completion by early Q4 2026 after protocol amendments expanded the patient pool to 164. The company also advanced its surgical AF ablation and soft tissue programs, including a new partnership for benign thyroid nodule treatment. Pulse Biosciences is a medical device company developing nanosecond pulsed field ablation technology for cardiac and soft tissue treatments.